Ozempic Weight Loss Results: Clinical Data & Genetic Factors

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) produces highly variable weight loss across individuals, with clinical trial data showing weight reductions ranging from 3% to 10% of body weight depending on baseline factors and adherence. Understanding what drives these differences can support a more realistic treatment discussion with your provider.

Weight loss outcomes depend on multiple factors beyond the medication alone: baseline metabolic health, genetic predispositions in GLP-1 signaling pathways, adherence patterns, and lifestyle integration. PlexusDx takes a precision-wellness approach by helping patients understand their individual context before and during treatment decisions.

Clinical Trial Data: What Real-World Weight Loss Looks Like

Landmark SUSTAIN trials evaluated semaglutide efficacy across 2–3 years. At the highest approved dose, participants achieved approximately 10% body weight reduction on average, though individual results ranged from minimal loss to 15% or greater.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Individual Response Variation: Biomarkers and Genetic Context

Not all GLP-1 medications work equally across all people. Differences in genetic variants affecting GLP-1 receptor (GLP1R) and glucose-dependent insulinotropic peptide receptor (GIPR) signaling may influence appetite suppression magnitude and metabolic effects, though genetic predisposition does not determine exact medication response.

Additional biomarkers—including insulin resistance patterns, baseline glucose control, and inflammatory markers—provide clinical context for how a patient's metabolic system may respond to GLP-1 therapy. These factors work alongside genetic variation to shape overall outcomes.

Factor	Clinical Relevance to Weight Loss Response
GLP1R Genetic Variants	May influence appetite-suppression intensity and satiety signaling; variants like rs6923761 are mapped by Precision Peptide testing
GIPR Pathway Variants	Associated with glucose metabolism and incretin response; rs1800437 variant may affect dual-pathway medications (tirzepatide)
Baseline Insulin Resistance	Higher HOMA-IR scores may correlate with greater early weight loss due to improved metabolic efficiency
Inflammatory Markers	Elevated CRP or IL-6 may be associated with metabolic dysfunction; GLP-1 therapy may reduce inflammation alongside weight loss

Timeline Expectations: When Weight Loss Plateaus and Stabilizes

Most GLP-1 weight loss occurs within the first 3–6 months as dose escalation proceeds and appetite suppression peaks. After reaching the maintenance dose, weight loss often slows significantly, then stabilizes over 12–24 months, reflecting a new metabolic equilibrium.

Sustained weight loss requires consistent adherence and lifestyle support. Patients who maintain dietary and activity changes alongside medication typically preserve weight loss longer than those who rely on medication alone. Provider support and realistic goal-setting improve long-term outcomes.

Who Is Most Likely to Achieve Meaningful Weight Loss: Eligibility and Provider Assessment

GLP-1 medications are most clearly indicated for individuals with BMI ≥27 and weight-related comorbidities (hypertension, prediabetes, PCOS) or BMI ≥30 regardless of comorbidity. Patients with type 2 diabetes benefit from both weight loss and glycemic control. Eligibility requires comprehensive medical evaluation by a qualified provider.

Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe gastroparesis. A provider-led assessment should address medication interactions, renal function, and psychiatric medication stability. This evaluation ensures safety and identifies candidates most likely to benefit.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test maps predispositions in key GLP-1 pathway variants (GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context for how your metabolic system responds to GLP-1 therapy. These results should be interpreted alongside clinical biomarkers by a qualified healthcare provider to support a more personalized treatment conversation.

The genetic test does not predict exact medication response or guarantee weight loss outcomes—genetics represents one layer of the personalization puzzle. Combined with baseline metabolic markers, lifestyle readiness, and medical history, genetic insight can help patients and providers align treatment selection with individual predisposition patterns.

Understanding your genetic and biomarker context supports a more informed dialogue about medication choice, dosing strategy, and realistic timelines. PlexusDx compounded GLP-1 options (semaglutide injection, oral semaglutide, tirzepatide injection, or dual-compound GLP-Squared) can be tailored based on this personalized assessment, providing a precision-wellness approach to weight management treatment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What average weight loss does this article report from the SUSTAIN trials?

The post says the landmark SUSTAIN trials evaluated semaglutide over two to three years and that participants at the highest approved dose achieved roughly 10 percent body weight reduction on average, with individual results running from minimal loss to 15 percent or greater. Its opening paragraph gives a narrower 3 to 10 percent range, so the article is not fully consistent on the spread.

When does this article say weight loss usually slows down?

According to the post, most GLP-1 weight loss occurs in the first three to six months while escalation proceeds and appetite suppression peaks. After the maintenance level is reached it says loss often slows significantly, then stabilizes across 12 to 24 months as the body settles into a new metabolic equilibrium. Adherence and lifestyle support are what it credits with protecting the result.

Which BMI thresholds does the article use to describe likely candidates?

The post says GLP-1 medications are most clearly indicated for people with a BMI of 27 or above who also have weight-related conditions such as hypertension, prediabetes, or PCOS, or a BMI of 30 or above regardless of other conditions. It adds that people with type 2 diabetes may see both weight and glycemic benefit, and that eligibility requires full provider evaluation.

Beyond thyroid history, what does the article say a provider assessment should cover?

The post says a provider-led assessment should address medication interactions, renal function, and psychiatric medication stability, on top of screening for contraindications such as personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe gastroparesis. It frames that evaluation as what both ensures safety and identifies who is most likely to benefit.

Which non-medication factors does this article link to keeping weight off?

The article says sustained results require consistent adherence plus lifestyle support, and that patients who maintain dietary and activity changes alongside treatment typically preserve weight loss longer than those relying on medication alone. It also credits provider support and realistic goal-setting with improving long-term outcomes, and names baseline metabolic health and adherence patterns as sources of variation.

Related Reading

• What Genetic Factors Determine How Much Sleep You Need Each Night
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.